Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00334204 · ClinicalTrials.gov registry record · Phase 4
Does An Abnormal PFA 100 Predict Bleeding After Renal Biopsy?
A Phase 4 study, sponsored by University of Mississippi Medical Center.
- Terminated
- Registry status
- Phase 4
- Development phase
- 58
- Enrollment target
NCT00334204: Clinical Trial Phase 4 study, sponsored by University of Mississippi Medical Center.
NCT00334204 is a Phase 4 study that was terminated before completion, run by University of Mississippi Medical Center. The registered enrollment target is 58 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00334204, a Phase 4 study, was terminated before completion, sponsored by University of Mississippi Medical Center.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 58 participants
- Enrollment target
Study Summary
The kidneys are highly vascular organs and any trauma or surgery poses risk of severe bleeding. Platelet function is an integral part of the blood clotting during the initial, so-called vascular phase. So far no universally accepted, easy test has been available to measure platelet functions. Renal failure is a condition generally associated with bleeding due to platelet dysfunctions. This study is exploring the utility of a novel platelet function test, called Platelet Function Analyser-100 to predict bleed after percutaneous kidney biopsy. Platelet Function Analyser-100 will be measure before kidney biopsy along with routine blood tests. Subjects will undergo renal ultrasound before and after renal biopsy to verify post-biopsy bleeding events.
Interventions
- DEVICE measuring Platelet Function Analyser-100 (PFA-100) platelet function before kidney biopsy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2004-08 |
| Est. Completion | 2008-12 |
| Phase | Phase 4 |
Why NCT00334204 stopped before completion
NCT00334204 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 1 intervention - of which measuring Platelet Function Analyser-100 (PFA-100) platelet function before kidney biopsy is the first listed.
NCT00334204 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00334204 about?
NCT00334204 is a clinical study titled "Does An Abnormal PFA 100 Predict Bleeding After Renal Biopsy?". The kidneys are highly vascular organs and any trauma or surgery poses risk of severe bleeding. Platelet function is an integral part of the blood clotting during the initial, so-called vascular phase. So far no universally accepted, easy test has been available to measure platelet functions. Renal ...
What is the current status of trial NCT00334204?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 58 participants. The study started on 2004-08. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00334204?
The interventions under investigation include: measuring Platelet Function Analyser-100 (PFA-100) platelet function before kidney biopsy (DEVICE).
Who is sponsoring clinical trial NCT00334204?
This trial is sponsored by University of Mississippi Medical Center, which has 96 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00334204's enrollment target sits among peer trials
58 1205th of 2000 higher than 792 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia